Gen-Wealth Partners
TNXP icon

Gen-Wealth Partners’s Tonix Pharmaceuticals TNXP Stock Holding History

Gen-Wealth Partners’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$5.19K Hold
533
– – ﹤0.01% 644
2026
Q2 		$6.8K Hold
533
– – ﹤0.01% 578
2026
Q1 		$7.33K Hold
533
– – ﹤0.01% 566
2025
Q4 		$8.32K Hold
533
– – ﹤0.01% 532
2025
Q3 		$12.9K Buy
+533
New +$19.8K ﹤0.01% 499

Other funds holding TNXP

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
JHC
Jones Hill Capital New York $589M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Essex Investment Management
Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Gen-Wealth Partners's TNXP Position: Q3 2026 in Review

Gen-Wealth Partners held its Tonix Pharmaceuticals (TNXP) position steady in Q3 2026 at 533 shares worth $5.19K. The position accounts for ﹤0.01% of the portfolio, ranked #644.

Gen-Wealth Partners first reported a position in TNXP in Q3 2025 and has held it in 5 quarters since. The position peaked at $12.9K in Q3 2025. 76 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

  • Gen-Wealth Partners held 533 shares of Tonix Pharmaceuticals worth $5.19K as of Q3 2026.
  • Gen-Wealth Partners left its Tonix Pharmaceuticals share count unchanged in Q3 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q3 2026, its #644 holding.
  • Gen-Wealth Partners first reported a position in Tonix Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • Gen-Wealth Partners's Tonix Pharmaceuticals position peaked at $12.9K in Q3 2025.
  • 76 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on Gen-Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.